Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Capital Expenditures: 2012-2024

Historic Capital Expenditures for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Dec 2024 value amounting to $41.0 million.

  • Amphastar Pharmaceuticals' Capital Expenditures fell 61.23% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 2.49%. This contributed to the annual value of $41.0 million for FY2024, which is 7.53% up from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Capital Expenditures of $41.0 million as of FY2024, which was up 7.53% from $38.2 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Capital Expenditures registered a high of $41.0 million during FY2024, and its lowest value of $24.0 million during FY2022.
  • Its 3-year average for Capital Expenditures is $34.4 million, with a median of $38.2 million in 2023.
  • In the last 5 years, Amphastar Pharmaceuticals' Capital Expenditures fell by 18.90% in 2021 and then soared by 58.80% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Capital Expenditures (Yearly) stood at $33.9 million in 2020, then fell by 18.90% to $27.5 million in 2021, then dropped by 12.46% to $24.0 million in 2022, then soared by 58.80% to $38.2 million in 2023, then grew by 7.53% to $41.0 million in 2024.